BISMUTH ALUMINATE

US Approved OTC

First approved in 1961

Details

Stereochemistry	ACHIRAL
Molecular Formula	6Al.2Bi.12O
Molecular Weight	771.8428
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3]

InChI

InChIKey=PDSAKIXGSONUIX-UHFFFAOYSA-N

InChI=1S/6Al.2Bi.12O/q8*+3;12*-2

HIDE SMILES / InChI

Molecular Formula	Bi
Molecular Weight	208.9804
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Al
Molecular Weight	26.9815386
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.omicsonline.org/medical-use-of-bismuth-the-two-sides-of-the-coin-2161-0495.S3-004.php?aid=5343 | https://www.ncbi.nlm.nih.gov/pubmed/14295334 | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1574810&blobtype=pdf | https://www.ncbi.nlm.nih.gov/pubmed/13502848

Bismuth aluminate is an antacid drug. The good therapeutic results are due to a coating effect providing a local antipepsin action at the site of the ulcer is an interesting possibility. Inorganic bismuth derivatives have good antibacterial properties and are considered to be only slightly toxic to humans because of their low uptake into human cells. The formation of methylated bismuth derivatives in the human gut may damage mammalian cells as well as the physiological gut microbiota.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Coating of the mucosa 1 Target ID: Coating of the mucosa Sources: https://www.ncbi.nlm.nih.gov/pubmed/14295334	Modulator 846
Peptic activity 1 Target ID: Peptic activity Sources: https://www.ncbi.nlm.nih.gov/pubmed/14295334	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Peptic ulcer 72 Sources: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1574810&blobtype=pdf http://ccne.mofcom.gov.cn/361391/p1997914.html	Palliative	Withdrawn	Estomul Approved Use Unknown
Gastritis 46 Sources: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1574810&blobtype=pdf http://ccne.mofcom.gov.cn/361391/p1997914.html	Palliative	Withdrawn	Estomul Approved Use Unknown
Gastroesophageal reflux 1 Sources: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1574810&blobtype=pdf http://ccne.mofcom.gov.cn/361391/p1997914.html	Palliative	Withdrawn	Estomul Approved Use Unknown
Esophagitis 4 Sources: https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1574810&blobtype=pdf http://ccne.mofcom.gov.cn/361391/p1997914.html	Palliative	Withdrawn	Estomul Approved Use Unknown

PubMed

Title	Date	PubMed
Preparation and cytocompatibility of a novel bismuth aluminate/calcium phosphate cement with high radiopacity.	2018-09-04	30182158
Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori.	2018	29636776
Monitoring and evaluating the quality consistency of Compound Bismuth Aluminate tablets by a simple quantified ratio fingerprint method combined with simultaneous determination of five compounds and correlated with antioxidant activities.	2015	25793599
[Bismuth aluminate in gastroenterology. Therapeutic effects in chronic erosive Campylobacter pylori-associated gastritis].	1989-10-10	2680842
[Formation of bismuth aluminate film on the gastric mucosa].	1972	5050006
An evaluation of a bismuth aluminate antacid.	1968-03	4966996
Further experience with bismuth aluminate in peptic ulceration and nervous dyspepsia.	1965-10	5830345
ACTION OF BISMUTH ALUMINATE.	1965-06-26	14295334

Patents

Sample Use Guides

In Vivo Use Guide

Liquid and tablets: 1 or 2 tablespoons or 1 or 2 tablets three times daily depending on severity of involvement.

Route of Administration: Oral

In Vitro Use Guide

Bismuth aluminate powder by Brindle’s method neutralises 70-88 per cent of acid in 20 minutes without an abnormal increase in pH and in therapeutic doses (0.7 g Bi).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:18 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:18 GMT 2025`
Record UNII	JB5Y63JDHJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BISMUTH ALUMINATE [MI]

Preferred Name

English

BISMUTH ALUMINATE

Official Name

English

Bismuth aluminate [WHO-DD]

Common Name

English

BISMUTH ALUMINATE [MART.]

Common Name

English

BISMUTH ALUMINATE [USAN]

Common Name

English

ALUMINUM BISMUTH OXIDE

Systematic Name

English

ALUMINIUM BISMUTH OXIDE

Systematic Name

English

Classification Tree Code System Code

CFR

21 CFR 331.11